Evommune (NYSE:EVMN) Stock Rating Upgraded by Wall Street Zen

Evommune (NYSE:EVMN) was upgraded by Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued to investors on Sunday.

A number of other brokerages have also weighed in on EVMN. Leerink Partners started coverage on Evommune in a research note on Monday, December 1st. They issued an “outperform” rating and a $42.00 price objective on the stock. Zacks Research raised Evommune to a “hold” rating in a report on Tuesday, December 2nd. William Blair started coverage on shares of Evommune in a research report on Monday, December 1st. They issued an “outperform” rating on the stock. Evercore ISI initiated coverage on shares of Evommune in a research report on Monday, December 1st. They set an “outperform” rating and a $40.00 price objective for the company. Finally, Morgan Stanley began coverage on shares of Evommune in a research note on Monday, December 1st. They issued an “overweight” rating and a $36.00 price objective on the stock. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has given a Hold rating to the company. According to MarketBeat, the company has a consensus rating of “Buy” and an average target price of $39.33.

Evommune Stock Performance

NYSE:EVMN opened at $17.82 on Friday. Evommune has a one year low of $16.70 and a one year high of $24.03.

Evommune (NYSE:EVMN) last announced its quarterly earnings results on Thursday, December 11th. The company reported ($8.07) earnings per share for the quarter, missing analysts’ consensus estimates of ($6.58) by ($1.49). The company had revenue of $10.00 million for the quarter, compared to analysts’ expectations of $10.00 million.

About Evommune

Evommune is a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria (“CSU”), atopic dermatitis (“AD”) and ulcerative colitis (“UC”). Chronic inflammation is a significant healthcare problem in the world, substantially impacting patients’ quality of life and leading to life-threatening conditions.